Therapeutic Research and Development
R&D response to COVID-19
Sources of R&D funding and collaboration
Clinical trials have increased
organizations have added new assets to pipeline
Therapeutics are typically antivirals or antibodies
promising therapeutics
promising therapeutics candidates
Therapeutics assets
Select therapeutics
important questions remain
asset-by-asset coverage

To spotlight key assets in development, case studies have been developed that provide an asset-by-asset overview of development plans, timelines, and reasons for optimism.

From the L.E.K. Healthcare Insights Center:

Eileen Coveney, Managing Director
Jonathan Kfoury, Managing Director
Kevin Giffels, Senior Associate Consultant
Rosie Jiang, Global Healthcare Specialist
Jeffrey Holder, Engagement Manager

Please reach out to us if you would like to continue the discussion.

Related Insights